发明授权
US07125845B2 Aza-peptide macrocyclic hepatitis C serine protease inhibitors
有权
Aza-peptide大环丙型肝炎丝氨酸蛋白酶抑制剂
- 专利标题： Aza-peptide macrocyclic hepatitis C serine protease inhibitors
- 专利标题（中）： Aza-peptide大环丙型肝炎丝氨酸蛋白酶抑制剂
-
申请号： US10613206申请日： 2003-07-03
-
公开(公告)号： US07125845B2公开(公告)日： 2006-10-24
- 发明人: Frank X. H. Wu , Suanne Nakajima , Zhi-Hui Lu , Ying Sun , Zhenwei Miao , Yat Sun Or , Zhe Wang
- 申请人： Frank X. H. Wu , Suanne Nakajima , Zhi-Hui Lu , Ying Sun , Zhenwei Miao , Yat Sun Or , Zhe Wang
- 申请人地址： US MA Watertown
- 专利权人： Enanta Pharmaceuticals, Inc.
- 当前专利权人： Enanta Pharmaceuticals, Inc.
- 当前专利权人地址： US MA Watertown
- 代理机构： Edwards angell Palmer & Dodge, LLP
- 代理商 Jeffrey D. Hsi; Dwight D. Kim
- 主分类号： A61K38/00
- IPC分类号： A61K38/00
摘要：
The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
公开/授权文献
信息查询
IPC分类:
